ADAP News and Press, Adaptimmune Therapeutics plc From 12/31/18

(Source: Evil Speculator) Anyone thinking 2018 investing hasn’t been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for ...

Adaptimmune Therapeutics PLC (ADAP) Q3 2018 Earnings Conference Call November 6, 2018 08:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Adrian Rawcliffe - Chief Financial Officer Analysts Jonathan Cha...

Adaptimmune (NASDAQ: ADAP ): Q3 GAAP EPS of $0.01 beats by $0.05 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...

Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019  ~$26 mill...

PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S. markets open on...

Gainers:  ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo...

ADAP   -34%  on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more ...

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) slumps  37%  premarket on light volume on the heels of its announcement of initial data from the first two cohorts of its ongoing studies evaluating its MAGE-A10 and MAGE-A4 SPEAR T-cells. The results were presented at ESMO in Munich. ...

PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MA...

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y...